Blandy Fisher
About Blandy Fisher
Blandy Fisher serves as the Director of Business Operations at Velocity Clinical Research, Inc., where he has worked since 2020. He has extensive experience in clinical trial management and patient recruitment, having previously managed recruitment for 16 sites and played a significant role in enrolling over 10,000 volunteers for COVID vaccine trials.
Current Role at Velocity Clinical Research
Blandy Fisher serves as the Director of Business Operations at Velocity Clinical Research, Inc. since 2020. In this role, he oversees operational data analytics across 80 clinical research sites in the U.S. and Europe. His responsibilities include managing business operations to enhance efficiency and effectiveness in clinical trials.
Previous Experience at Velocity Clinical Research
Prior to his current position, Blandy Fisher worked at Velocity Clinical Research, Inc. as the Manager of Site Support from 2018 to 2020. During this time, he managed patient recruitment for 16 clinical trial sites across the U.S., contributing to the overall success of clinical research initiatives.
Career Background in Clinical Research
Blandy Fisher has extensive experience in clinical research, having worked at Quintiles in various roles from 2005 to 2010. His positions included Senior Proposal Developer, Manager of Competitive Intelligence and Analysis, and Project Manager. His work involved strategic planning and project management within the clinical trial landscape.
Educational Background
Blandy Fisher holds a Bachelor of Arts in Classical Studies and Art History from Duke University, which he completed from 1981 to 1985. He furthered his education at North Carolina State University, earning a Master of Science in Industrial and Organizational Psychology from 2000 to 2003.
Achievements in Clinical Trials
Blandy Fisher played a significant role in enrolling over 10,000 volunteers for COVID vaccine trials during the initial eight months of research. His efforts were crucial in facilitating the rapid recruitment necessary for the clinical trials that contributed to vaccine development.